Standard electrode potential

Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Monday, November 28, 2022
American Epilepsy Society, Seizure, Brain, EEG, Oxcarbazepine, Security (finance), Government budget balance, DEE, Intellectual disability, Neuron, Patient, Pharmacokinetics, European Medicines Agency, Șaeș, Heart rate, Cyanosis, SCN8A, NAV, Caregiver, Movement, Iňa, Fed, FDA, COVID-19, Dees, Judgement, Epilepsy, Body part as an object, Ataxia, Food, Standard electrode potential, Life, Central nervous system disease, Disease, Orphan, AES, Annual general meeting, Central nervous system, CNS, Dystonia, ODD, Movement disorders, Pharmaceutical industry, Generic drug, Part, Safety, Praxis, SCN2A

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.

Key Points: 
  • BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.
  • Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
  • Although Praxis forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies

Retrieved on: 
Monday, November 28, 2022
COVID-19, Dees, Patient, Judgement, Epilepsy, Intellectual disability, European Medicines Agency, Ataxia, Heart rate, Pharmacokinetics, Food, Cyanosis, SCN8A, NAV, Safety, Standard electrode potential, Life, Brain, Caregiver, Central nervous system disease, Movement, Food and Drug Administration, Seizure, Central nervous system, Orphan, CNS, Dystonia, Security (finance), Government budget balance, DEE, Neuron, ODD, FDA, Movement disorders, Pharmaceutical industry, Praxis, SCN2A

The EMBOLD Study is expected to initiate in the U.S in the first quarter of 2023, with two distinct cohorts in early-onset SCN2A-DEE and SCN8A-DEE patients.

Key Points: 
  • The EMBOLD Study is expected to initiate in the U.S in the first quarter of 2023, with two distinct cohorts in early-onset SCN2A-DEE and SCN8A-DEE patients.
  • Approximately 20 participants will be enrolled in a total of 2 distinct cohorts (n10 for SCN2A-DEE and n10 for SCN8A-DEE).
  • PRAX-562 has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel blocking effects.
  • Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.

Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs

Retrieved on: 
Wednesday, September 7, 2022
COVID-19, Safety, Brain, Intellectual disability, U.S. Securities and Exchange Commission, GLOBE, Standard electrode potential, Twitter, Adult, Patient, EMA, RPD, DEE, Survival, Movement disorders, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Seizure, Lists of diseases, Collection, Food, Private Securities Litigation Reform Act, Headache, IONS, FDA, Ataxia, SCN8A, Government budget balance, Trial of the century, Investigational New Drug, Security (finance), Central nervous system disease, Heart rate, Neuron, NASDAQ, Judgement, LinkedIn, ODD, Cyanosis, Dees, Ionis Pharmaceuticals, Epilepsy, Review, ASO, European Medicines Agency, Central nervous system, Dystonia, Goal, Movement, CNS, Life, Pharmaceutical industry, Vaccine, Praxis, IND, SCN2A

Following the clearance of the initial IND last year, Praxis completed the chronic and juvenile toxicology programs and submitted a second IND to the FDA.

Key Points: 
  • Following the clearance of the initial IND last year, Praxis completed the chronic and juvenile toxicology programs and submitted a second IND to the FDA.
  • Praxis has initiated discussions with the FDA to provide clarification about the pre-clinical and clinical data packages in relation to the clinical hold correspondence.
  • Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
  • Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with four clinical-stage product candidates.

Rune Labs Partners with Coastal Research Institute to Identify Biomarkers of Multiple Sclerosis Lesions using AI Platform to Analyze Patient Neurophysiological Data

Retrieved on: 
Thursday, July 14, 2022
Eclipse, Technology, Disease, EDSS, Nerve, José Benito Vives de Andréis Marine and Coastal Research Institute, Leadership, Neuropathic pain, Multiple sclerosis, Patient, CRI, Spine, SAN, Demyelinating disease, MD, Brain, Physician, Runes, Parkinson's disease, Pathology, Spinal cord, Machine learning, Trial of the century, Therapy, Remyelination, Standard electrode potential, Data analysis, MS, Research, Immune system, Degenerative disease, Physiology, Doctor of Philosophy, Software, Institute, Biomarker, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, July 14, 2022 /PRNewswire/ -- Rune Labs, a precision neurology software and data platform company, today announced it is enrolling patients with multiple sclerosis (MS) in a study to identify neurophysiological biomarkers of the disease. The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology. Demyelination is a hallmark symptom of MS that occurs when the immune system attacks nerve fibers, causing lesions in the brain and spine. 

Key Points: 
  • The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology.
  • Clinical scores currently used as endpoints and screeners in trials are imprecise and do not always correlate with lesion activity.
  • "Rune's AI platform enables us to take raw brain data and convert it into actionable biomarkers of myelination."
  • Rune Labs' first-in-class precision neurology software platform uses machine learning to capture and analyze electrophysiological brain data to uncover previously overlooked markers of disease.

Curi Bio Acquires CarTox™ Technology from StemBioSys, Announces Launch of Nautilus™ Optical Mapping System

Retrieved on: 
Tuesday, March 29, 2022
Research, General Health, Pharmaceutical, Oncology, Genetics, Clinical Trials, Science, Engineering, Cardiology, Biotechnology, Stem Cells, Health, Manufacturing, Bio, Drug development, Cell, Booth, Health, SBS, 2D, Therapy, Â, Marketing, 3D, Society, Multimedia, Electrophysiology, Natural scientific research in Canada, Standard electrode potential, Research, CEO, Scientific Reports, Tissue, Calcium, Technology, Safety, Acquisition, NIH, CIPA, Workflow, B cell, Extracellular matrix, Drug discovery, Nautilus, Curi, University, Pharmaceutical industry, Medical imaging, Pulse, CURI BIO, STEMBIOSYS, INC.

In parallel, Curi Bio announced it will commercialize the technology through its newly announced product: the Nautilus optical mapping system.

Key Points: 
  • In parallel, Curi Bio announced it will commercialize the technology through its newly announced product: the Nautilus optical mapping system.
  • Curi will make the Nautilus system available to pharmaceutical and research customers as a standalone bioscience instrument, compatible with Curi Bios market-leading cloud-based data analytics platforms.
  • Curi will also offer service contracts and partnerships leveraging the system for applications in drug discovery, disease modeling, and safety and efficacy screening.
  • The Nautilus system enables researchers the ability to condense days of data acquisition and analysis to minutes via an automated workflow.

NIH/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States

Retrieved on: 
Thursday, September 30, 2021
Food, Gabapentin, SBIR, Initiative, Chronic pain, Food and Drug Administration, Research, National, Pain management, Investigational New Drug, NINDS, Patient, Itch, Pain, Lists of diseases, SAN, Cros, Risk, Standard electrode potential, Degenerative disease, National Institute, Fortune 500, Neuropathic pain, NIH, Pregabalin, Sodium, Safety, National Institute of Neurological Disorders and Stroke, GLOBE, Neuron, Pharmaceutical industry

AnaBios is developing ANB-504, a lead small molecule dual inhibitor of two sodium channels specifically expressed in sensory neurons and implicated in numerous forms of chronic pain.

Key Points: 
  • AnaBios is developing ANB-504, a lead small molecule dual inhibitor of two sodium channels specifically expressed in sensory neurons and implicated in numerous forms of chronic pain.
  • ANB-504 shows potent, dose-dependent inhibition of action potentials in human sensory neurons in a variety of pathological states and is intended for the treatment of mixed inflammatory and neuropathic pain.
  • "AnaBios appreciates NIH's support in our continued effort to bring a potential new, non-addictive pain therapy to market," said Dr. Andre Ghetti, Chief Executive Officer of AnaBios.
  • Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies.

Contrary to Expectations, Study Finds Primate Neurons Have Fewer Synapses Than Mice in Visual Cortex

Retrieved on: 
Tuesday, September 14, 2021
Science, Other Science, University, Research, Education, Neuron, Adult, Primate, Synapse, Standard electrode potential, Cell, Argonne National Laboratory, Mouse, Cell Reports, Research, University, Microscopy, Visual cortex, Chicago (franchise), Aroma compound

In a study comparing the brains of macaques and mice at the synaptic level, the researchers found that the primates had far fewer synapses per neuron compared to the rodents, in both excitatory and inhibitory neurons in layer 2/3 of the primary visual cortex.

Key Points: 
  • In a study comparing the brains of macaques and mice at the synaptic level, the researchers found that the primates had far fewer synapses per neuron compared to the rodents, in both excitatory and inhibitory neurons in layer 2/3 of the primary visual cortex.
  • They chose to examine both excitatory and inhibitory synapses, as most previous research had focused on only excitatory synapses.
  • Focusing on layer 2/3 neurons in the adult primary visual cortex made it easier to compare across species, as these neurons have distinct morphologies that are similar in both primates and mice.
  • Upon comparing the datasets, they found that primate neurons receive two to five times fewer excitatory and inhibitory synaptic connections than similar mouse neurons.